Fmr LLC Silverback Therapeutics, Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Silverback Therapeutics, Inc. stock. As of the latest transaction made, Fmr LLC holds 1,085,318 shares of SBTX stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,085,318

Previous 1,084,922 0.04%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	N/A	396 Added 0.04%	1,085,318 $0
Q1 2024 May 13, 2024	SELL	N/A	-117,393 Reduced 9.76%	1,084,922 $0
Q4 2023 Feb 13, 2024	SELL	N/A	-105,025 Reduced 8.03%	1,202,315 $0
Q3 2023 Nov 13, 2023	SELL	N/A	-3,357,438 Reduced 71.97%	1,307,340 $0
Q2 2023 Aug 11, 2023	SELL	N/A	-423,475 Reduced 8.32%	4,664,778 $0
Q1 2023 May 11, 2023	SELL	N/A	-281,109 Reduced 5.24%	5,088,253 $0
Q4 2022 Feb 13, 2023	BUY	$0.0 - $6.07 $0 - $3.68 Million	605,813 Added 12.72%	5,369,362 $0
Q3 2022 Nov 10, 2022	BUY	$3.91 - $5.52 $4.09 Million - $5.77 Million	1,045,097 Added 28.11%	4,763,549 $25.2 Million
Q2 2022 Aug 12, 2022	SELL	$2.9 - $4.44 $216,688 - $331,756	-74,720 Reduced 1.97%	3,718,452 $15.8 Million
Q1 2022 May 13, 2022	BUY	$3.51 - $6.74 $138,416 - $265,791	39,435 Added 1.05%	3,793,172 $13.3 Million
Q4 2021 Feb 14, 2022	SELL	$6.03 - $11.67 $3.22 Million - $6.24 Million	-534,812 Reduced 12.47%	3,753,737 $25 Million
Q3 2021 Nov 15, 2021	SELL	$9.98 - $35.22 $3.99 Million - $14.1 Million	-399,419 Reduced 8.52%	4,288,549 $42.8 Million
Q2 2021 Aug 13, 2021	BUY	$24.71 - $44.28 $116 Million - $208 Million	4,687,968 New	4,687,968 $145 Million

Others Institutions Holding SBTX

# of Institutions

122

Shares Held

61.4M

Call Options Held

1.37M

Put Options Held

83.8K

View Full List

About Silverback Therapeutics, Inc.

Ticker SBTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,473,800
Description
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverba...

More about SBTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account